AIMS: To evaluate the usefulness of molecular markers in predicting histopathological and clinical response to preoperative high dose chemotherapy (HDCT) and survival of patients with advanced gastric cancer. METHODS: In a phase II trial, 25 patients with metastatic gastric cancer received preoperative tandem HDCT consisting of etoposide, cisplatin, and mitomycin, followed by autologous bone marrow transplantation to achieve surgical resectability. Samples before and after treatment, from normal and tumour tissue, were characterised histopathologically, and both p53 and BAX expression was analysed by immunohistochemistry. Pretreatment formalin fixed, paraffin wax embedded samples from normal and tumour tissue were microdissected, and the extracted DNA was preamplified using improved primer extension preamplification polymerase chain reaction. Detection of microsatellite instability (MSI) or loss of heterozygosity (LOH) was performed using markers for p53, BAX, BAT25, BAT26, D2S123, D17S250, and APC. Exons 5-9 of the p53 gene were sequenced directly on ABI 373. RESULTS: Four parameters were significantly associated with response to chemotherapy and prolonged overall survival: positive p53 immunostaining, positive p53 mutation status before chemotherapy, strong histological regression induced by preoperative HDCT, and surgical treatment. Patients's sex or age, tumour location or stage, lymph node status, Lauren classification, MSI, or LOH did not influence duration of survival significantly in this high risk population. CONCLUSION: Positive p53 immunostaining and p53 mutation status in pretreatment tumour biopsies might be useful molecular predictors of response and prognosis in patients with advanced gastric cancer treated by preoperative HDCT.
AIMS: To evaluate the usefulness of molecular markers in predicting histopathological and clinical response to preoperative high dose chemotherapy (HDCT) and survival of patients with advanced gastric cancer. METHODS: In a phase II trial, 25 patients with metastatic gastric cancer received preoperative tandem HDCT consisting of etoposide, cisplatin, and mitomycin, followed by autologous bone marrow transplantation to achieve surgical resectability. Samples before and after treatment, from normal and tumour tissue, were characterised histopathologically, and both p53 and BAX expression was analysed by immunohistochemistry. Pretreatment formalin fixed, paraffin wax embedded samples from normal and tumour tissue were microdissected, and the extracted DNA was preamplified using improved primer extension preamplification polymerase chain reaction. Detection of microsatellite instability (MSI) or loss of heterozygosity (LOH) was performed using markers for p53, BAX, BAT25, BAT26, D2S123, D17S250, and APC. Exons 5-9 of the p53 gene were sequenced directly on ABI 373. RESULTS: Four parameters were significantly associated with response to chemotherapy and prolonged overall survival: positive p53 immunostaining, positive p53 mutation status before chemotherapy, strong histological regression induced by preoperative HDCT, and surgical treatment. Patients's sex or age, tumour location or stage, lymph node status, Lauren classification, MSI, or LOH did not influence duration of survival significantly in this high risk population. CONCLUSION: Positive p53 immunostaining and p53 mutation status in pretreatment tumour biopsies might be useful molecular predictors of response and prognosis in patients with advanced gastric cancer treated by preoperative HDCT.
Authors: T Grundei; H Vogelsang; K Ott; J Mueller; M Scholz; K Becker; U Fink; J R Siewert; H Höfler; G Keller Journal: Clin Cancer Res Date: 2000-12 Impact factor: 12.531
Authors: A M Chiaravalli; M Cornaggia; D Furlan; C Capella; R Fiocca; G Tagliabue; C Klersy; E Solcia Journal: Virchows Arch Date: 2001-08 Impact factor: 4.064
Authors: D Fink; S Nebel; P S Norris; R N Baergen; S P Wilczynski; M J Costa; M Haas; S A Cannistra; S B Howell Journal: Int J Cancer Date: 1998-08-31 Impact factor: 7.396
Authors: A Hartmann; H Blaszyk; R M McGovern; J J Schroeder; J Cunningham; E M De Vries; J S Kovach; S S Sommer Journal: Oncogene Date: 1995-02-16 Impact factor: 9.867
Authors: J G Williams; S E Roberts; M F Ali; W Y Cheung; D R Cohen; G Demery; A Edwards; M Greer; M D Hellier; H A Hutchings; B Ip; M F Longo; I T Russell; H A Snooks; J C Williams Journal: Gut Date: 2007-02 Impact factor: 23.059
Authors: Andrea Rodrigues Gonçalves; Antonio Jose Vasconcellos Carneiro; Ivanir Martins; Paulo Antonio Silvestre de Faria; Maria Aparecida Ferreira; Eduardo Linhares Riello de Mello; Homero Soares Fogaça; Celeste Carvalho Siqueira Elia; Heitor Siffert Pereira de Souza Journal: Pathol Oncol Res Date: 2010-11-30 Impact factor: 3.201
Authors: Robert Juvan; Petra Hudler; Barbara Gazvoda; Stanislav Repse; Matej Bracko; Radovan Komel Journal: Croat Med J Date: 2007-04 Impact factor: 1.351
Authors: Ronald van Eijk; Marjo van Puijenbroek; Amiet R Chhatta; Nisha Gupta; Rolf H A M Vossen; Esther H Lips; Anne-Marie Cleton-Jansen; Hans Morreau; Tom van Wezel Journal: J Mol Diagn Date: 2009-12-03 Impact factor: 5.568